Maximizing CD8+ T cell responses elicited by peptide vaccines containing CpG oligodeoxynucleotides
- 1 August 2007
- journal article
- research article
- Published by Elsevier in Clinical Immunology
- Vol. 124 (2) , 119-130
- https://doi.org/10.1016/j.clim.2007.04.003
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
This publication has 35 references indexed in Scilit:
- Vaccination regimens incorporating CpG-containing oligodeoxynucleotides and IL-2 generate antigen-specific antitumor immunity from T-cell populations undergoing homeostatic peripheral expansion after BMTBlood, 2007
- Immunologic and Clinical Outcomes of Vaccination With a Multiepitope Melanoma Peptide Vaccine Plus Low-Dose Interleukin-2 Administered Either Concurrently or on a Delayed ScheduleJournal of Clinical Oncology, 2004
- Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-reactive CD8+ T CellsThe Journal of Experimental Medicine, 2003
- Randomized Study of High-Dose and Low-Dose Interleukin-2 in Patients With Metastatic Renal CancerJournal of Clinical Oncology, 2003
- Adjuvant Immunization of HLA-A2–Positive Melanoma Patients With a Modified gp100 Peptide Induces Peptide-Specific CD8+T-Cell ResponsesJournal of Clinical Oncology, 2003
- Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor LymphocytesScience, 2002
- GM‐CSF‐based cancer vaccinesImmunological Reviews, 2002
- CpG Motifs in Bacterial DNA and Their Immune EffectsAnnual Review of Immunology, 2002
- Elucidating the Autoimmune and Antitumor Effector Mechanisms of a Treatment Based on Cytotoxic T Lymphocyte Antigen-4 Blockade in Combination with a B16 Melanoma VaccineThe Journal of Experimental Medicine, 2001
- Identification of Tyrosinase-related Protein 2 as a Tumor Rejection Antigen for the B16 MelanomaThe Journal of Experimental Medicine, 1997